全文获取类型
| 收费全文 | 22837篇 |
| 免费 | 1421篇 |
| 国内免费 | 168篇 |
学科分类
| 医药卫生 | 24426篇 |
出版年
| 2023年 | 259篇 |
| 2022年 | 301篇 |
| 2021年 | 1392篇 |
| 2020年 | 749篇 |
| 2019年 | 939篇 |
| 2018年 | 1251篇 |
| 2017年 | 729篇 |
| 2016年 | 795篇 |
| 2015年 | 801篇 |
| 2014年 | 1119篇 |
| 2013年 | 1326篇 |
| 2012年 | 1881篇 |
| 2011年 | 2044篇 |
| 2010年 | 1163篇 |
| 2009年 | 870篇 |
| 2008年 | 1201篇 |
| 2007年 | 1204篇 |
| 2006年 | 1108篇 |
| 2005年 | 1044篇 |
| 2004年 | 905篇 |
| 2003年 | 843篇 |
| 2002年 | 737篇 |
| 2001年 | 174篇 |
| 2000年 | 145篇 |
| 1999年 | 142篇 |
| 1998年 | 90篇 |
| 1997年 | 85篇 |
| 1996年 | 91篇 |
| 1995年 | 72篇 |
| 1994年 | 67篇 |
| 1993年 | 54篇 |
| 1992年 | 57篇 |
| 1991年 | 74篇 |
| 1990年 | 70篇 |
| 1989年 | 56篇 |
| 1988年 | 59篇 |
| 1987年 | 53篇 |
| 1986年 | 44篇 |
| 1985年 | 42篇 |
| 1984年 | 47篇 |
| 1983年 | 38篇 |
| 1982年 | 35篇 |
| 1981年 | 25篇 |
| 1980年 | 22篇 |
| 1978年 | 18篇 |
| 1977年 | 15篇 |
| 1976年 | 25篇 |
| 1975年 | 16篇 |
| 1974年 | 15篇 |
| 1973年 | 24篇 |
排序方式： 共有10000条查询结果，搜索用时 234 毫秒
1.
2.
3.
4.
5.
Khaled Adil Marija Popovic Fabio L. Cury Sergio L. Faria Marie Duclos Luis Souhami 《Practical radiation oncology》2019,9(1):24-28
Purpose
This study aimed to investigate 3 planning target volume (PTV) margin expansions and determine the most appropriate volume to be used in bladder preservation therapy when using daily cone beam computed tomography (CBCT). We aimed to establish whether a smaller PTV expansion is feasible without risking geographical miss.Methods and materials
The study included patients with bladder cancer who were treated with a hypofractionated course of radiation therapy delivered with intensity modulated radiation therapy. The clinical target volume (CTV) was the whole empty bladder, and the PTV consisted of a 1.5-cm margin around the bladder (PTV1.5 cm). Patients underwent daily CBCT imaging before treatment to assess the bladder volume and ensure accurate positioning. We investigated 2 additional smaller PTV margin expansions to determine the most appropriate volume to be used with CBCT as a daily image guided radiation therapy modality. These margins were created retrospectively on every CBCT. The first additional volume was a uniform PTV margin of the surrounding 1 cm (PTV1 cm). When considering that the majority of the internal bladder movement was due to the variation in filling that occurs in the superior and anterior directions, a second volume of an anisotropic PTV margin with a 1.5-cm superior/anterior and 1 cm in other directions (PTV1/1.5 cm) was created. We recorded the frequency and measured the volume of bladder falling out of each PTV based on the daily CBCT.Results
For the purpose of this study, we considered an arbitrary 5 cm3 of CTV falling out of the designated PTV as a clinically significant volumetric miss. The frequency of such a miss when applying the uniform PTV1 cm was 1%. However, when applying the uniform PTV1.5 cm and anisotropic PTV1/1.5 cm margins, the frequency was 0.5% and 0.5%, respectively.Conclusions
The anisotropic PTV expansion of 1.5 cm superiorly and anteriorly and 1 cm in all other directions around the bladder (CTV) provides a safe PTV approach when daily CBCT imaging is used to localize an empty bladder. 相似文献6.
7.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献8.
9.
10.
Lamberto Torralba‐Raga Bianca Tesi Samuel C. C. Chiang Heinrich Schlums Magnus Nordenskjld AnnaCarin Horne Jan‐Inge Henter Marie Meeths Mohamed Abdelhaleem Sheila Weitzman Yenan Bryceson 《Pediatric blood & cancer》2020,67(4)
Mutations in SH2D1A, encoding the intracellular adaptor signaling lymphocyte activation molecule associated protein (SAP), are associated with X‐linked lymphoproliferative disease type 1 (XLP1). We identified a novel hemizygous SH2D1A c.49G > A (p.E17K) variant in a 21‐year‐old patient with fatal Epstein‐Barr virus infection–associated hemophagocytic lymphohistiocytosis. Cellular and biochemical assays revealed normal expression of the SAP variant protein, yet binding to phosphorylated CD244 receptor was reduced by >95%. Three healthy brothers carried the SH2D1A c.49G > A variant. Thus, data suggest that this variant represents a pathogenic mutation, but with variable expressivity. Importantly, our results highlight challenges in the clinical interpretation of SH2D1A variants and caution in using functional flow cytometry assays for the diagnosis of XLP1. 相似文献
